A phospholipid previously shown to be converted to a lysophospholipid renin inhibitor has been demonstrated in the plasma and red cells of man and the dog. This inhibitor precursor, designated preinhibitor, is chromatographically identical to the compound previously isolated from kidneys of dogs and hogs. A method for its quantitative measurement in plasma and red cells is presented. Normal dogs tested so far have an average of 119.6 fig of preinhibitor phospholipid/ml of blood; 16.3 fig of this is in the plasma. These concentrations are constant (in red cells even increased) 48 hr after bilateral nephrectomy. To assess the physiological importance of preinhibitor, it may be necessary to measure its active lyso derivative as well as the Hpase(s) most directly involved in maintaining blood levels of these two phospholipids.
• A new phosphatidyl amino acid isolated from dog and hog kidneys (1) has been found to inhibit the enzyme renin indirectly and reduce the blood pressure of renal hypertensive rats (2) . It is the precursor of a second compound, a lysophospholipid, which migrates more slowly on our thin-layer chromatographic systems (1) . When this precursor phospholipid was incubated with dog renin and dog renin substrate, angiotensin production was inhibited and most of the phospholipid recovered at the end of incubation was the lysophospholipid (2) . We have assumed that the Hpase(s) responsible for this conversion were present as contaminants of the renin or substrate proteins. Immediate inhibition with smaller concentrations was achieved when lysophospholipid was added directly to the incubation medium, from which we infer that the lyso derivative, rather than the precursor, is the inhibiting agent (2) .
The present study was undertaken to show whether the precursor of the inhibitor (here called preinhibitor) is present in blood and to devise a method for detennining it. Blood from intact and bilaterally nephrectomized dogs was used to determine the preinhibitor in both plasma and red cells. Preliminary findings with the preinhibitor in human plasma and red cells are also presented.
Methods

BLOOD SAMPLING
Dogs.-We used healthy, unanesthetized dogs that had been fasted overnight. We withdrew approximately 25 ml of their blood from a femoral vein into a plastic disposable syringe containing 0.3 ml of 10% EDTA (disodium ethylenediamine tetraacetate) in distilled water. The sample was cooled in ice immediately. Under barbiturate anesthesia, the dogs were then bilaterally nephrectomized through a flank incision. Blood samples were collected in the same way 44 to 48 hr postoperatively.
Humans.-We used outdated human blood from the Cleveland Clinic Blood Bank. Total volume of the blood was 564 ml, which included 120 ml of anticoagulant containing 1.47 g of dextrose, 1.32 g of sodium citrate, and 0.44 g of anhydrous citric acid/100 ml of solution.
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OSTROVSKY, SEN, SMEBY, BUMPUS PREPARATION OF PLASMA AND WASHED RED CELLS
After withdrawing samples to determine hematocrit and total phosphorus, we centrifuged the chilled blood at 700 g for 20 min at 4°C. Plasma was separated from the packed red cells, which were then resuspended in approximately 5 volumes of chilled 0.9% sodium chloride and centrifuged. The white cell layer was largely removed by suction before and after washing. The red cells were transferred with chilled 0.9% saline into a 10-ml volumetric flask in a concentration approximately that of normal blood, and the hemoglobin in a solution of 0.02 ml of blood in 5.0 ml of Drabkin's reagent (3) was determined, using a flow-through model Fisher Hemophotometer. Phosphorus concentration was determined in all blood plasma and lipid samples by a modification of the method of Fiske and Sub-baRow (4) . Perchloric acid (10%) was used instead of sulfuric for digestion, and molybdate II reagent was used for producing phosphomolybdic acid. Total plasma proteins were determined by the biuret test (5) .
EXTRACTION OF CRUDE LIPIDS
Our method was a combination of procedures used by Nelson and Freeman (6) and Marks et al. (7) . Plasma (4.0 ml) was slowly added to 35 ml of redistilled methanol in a semimicro Monel metal container of a Waring Blendor operated at medium speed. Erythrocyte lipids were extracted from samples calculated to contain 0.5 g of hemoglobin. To facilitate extraction, Johns Manville celite or standard grade Whatman cellulose powder (2.4 g) and 1.0 g of urea were added to the methanol before introducing the red cells. With the blender still in operation, 70 ml of chloroform was introduced and blending continued for 7 min. The resulting mixture was poured quickly into a filter funnel (Whatman No. 1 filter paper) and the blender and residue were washed with 2 parts chloroform-1 part methanol (C:M, 2:1). The filtered extract was washed three times with 1/5 volumes of distilled water in a separatory funnel, and the final clear, pale lower organic phase was reduced in volume under vacuum, until near dryness. The lipid concentrate was transferred quantitatively into tared vials using either chloroform-methanol or ether, and excess solvent was evaporated under a stream of nitrogen. Before weighing, the product was dried overnight under reduced pressure in a desiccator (which had been flushed with nitrogen before evacuation), containing paraffin shavings, sodium hydroxide, and phosphorus pentoxide. Dry lipid samples were stored under nitrogen in sealed vials, at 5°C before use.
RECOVERY STUDIES
To test the effectiveness of the first extraction, the filter paper and precipitates were reextracted singly or in pools of two or more, and the lipid yield from the second extract was determined as described previously. The products from the first and second extractions were added, and the yield from the first extraction was expressed as a percentage of this sum.
SILICIC ACID COLUMN CHROMATOGRAPHY
Mallinckrodt 100-200 mesh silicic acid (SilicAR CC-4) for chromatography was activated at 110°C overnight, cooled in a descicator and suspended in C:M (9:1) and decanted three times for removal of fines. Teflon-stoppered columns approximately 40 cm long and 1 cm i.d. were packed with 12 to 14 g per column to provide 0.5 to 1 g of dry silicic acid/mg of applied lipid. Flow rates usually did not exceed 1 ml/min. Crude lipid extracts from plasma or red cells were dissolved in 2 ml of C:M (9:1), and after removing 0.05 ml and 0.1 ml, respectively, for determination of lipid phosphorus, the remainder was divided equally between duplicate columns. About 2K bed volumes of C:M (9:1) were used to elute neutral lipids and other impurities. The column was next eluted with 50 ml of C:M (6:1) mixture, which removed most or all of the phosphatidyl ethanolamine from the sample. Finally, the columns were eluted with C:M (4:1) mixture, of which the first 125 ml was collected. This portion constituted the "preinhibitor fraction," which was concentrated almost to dryness in a flash evaporator and the residue transferred with ether to a small vial. Excess ether was driven off by a stream of nitrogen, and the residue quantitatively applied to a thin-layer sheet as a spot or short line as described below. The C:M (9:1) and C:M (6:1) eluates, after concentration, were checked on several occasions for presence of preinhibitor. Negligible or no traces were found once the method was standardized, and only in the C:M (6:1) fraction, with volumes greater than 50 ml. Whenever necessary, upon removal of the preinhibitor in C:M (4:1) all the phosphorus was eluted from the column with C:M (1:9). This "final fraction" was concentrated, and checked by thin-layer chromatography for absence of preinhibitor.
THIN-LAYER CHROMATOGRAPHY
Eastman chromatogram sheets type K 301 R2 (Silica Gel) without fluorescent indicator were used for most experiments. The 20 X 20 cm sheets were activated at 100 to 110°C for 30 to 60 min before spotting and developed in the first dimension with Wuthier's solvent system no. 1 (8) , which is 23 ml of chloroform, 10 ml of methanol, 45 ml of diisobutylketone, 25 ml of acetic acid, and 4 ml of water. Wuthier's solvent system no. 3 was used in the second dimension. This system Apparatus for quantitative removal of areas containing preinhibiior from developed thin-layer chromatography plates.
included 30 ml of chloroform, 17.5 ml of methanol, 25 ml of diisobutylketone, 35 ml of pyridine, and 0.5 M ammonium chloride buffer at pH 10.4. After development, the preinhibitor spot was visualized by spraying the plate with ninhydrin reagent and heating for 5 min at about 70°C. The spot was moistened very slightly with distilled water, and transferred to a digestion tube containing perchloric acid by sucking the coating off through P.E. 206 polyethylene tubing ( Fig.  1 ). Scrapings remaining in the tubing were flushed into the perchloric acid with distilled water. Digestion was completed in a sand bath at about 180°C. The contents were transferred quantitatively to 10-ml volumetric flasks after filtering through Whatman No. 1 filter paper 5.5 cm in diameter. The flasks were made up to the mark with the appropriate reagents and rinsings of distilled water, and the phosphorus concentration was determined. The phospholipid represent- ed was calculated as 26.3 X P (1) . No phosphorus was detected in the total silica gel coating scraped from up to 9 cm 2 of developed blank chromatography plates. However, blank tubes were usually prepared from digests of an area of blank coating that had been sprayed with ninhydrin and was comparable in area to the largest spot analyzed in a particular run.
ASSAY OF PREINHIBITOR
The system for assaying inhibition of renin was that described earlier (1) with the following modifications. To each incubation tube was added 2 ml of dog renin substrate containing 0.44 mg of protein/ml, 0.1 ml of dog renin (1), 0.3 ml of ethylene glycol (vehicle for addition of preinhibitor phospholipid), and 1 drop of DFP made up a total incubation volume of 2.4 ml. This system generated 40 ng of angiotensin/ml in 4 hr.
Results
EFFICIENCY OF LIPID EXTRACTION FROM PLASMA AND RED CELLS
A sample of freshly drawn blood from a normal male dog was divided into five 4-mI aliquots of plasma and five aliquots of washed red cells containing 0.5 g of hemoglobin.
Weights of lipids extracted from these are shown in Table 1 ; the agreement among them is quite satisfactory. In a different experiment, samples of 4.0 ml of plasma and red cells (0.5 g of hemoglobin) from 6 intact control dogs were extracted; averages from duplicate determinations are recorded in Table 2 .
Filter papers, together with the adherent residues from 19 different plasma extractions, were extracted a second time, and the resulting lipids were pooled. An average of 4.06 mg of "lipid" per filter paper was recovered. This represents 11.1* of the 36.6-mg sum of averages derived from both extractions in this series. Therefore 88.93! of the lipid was recovered in the first extraction. By the same process of computation the recovery of red cell lipids from the first extraction averaged consistently about 76%. Much of the so called "lipid" obtained by the second extraction, especially of red cells, was insoluble in ether and therefore probably not material of interest to this study. Hence no effort was made to improve these recovery figures. 
RECOVERY OF PREINHIBITOR FROM SILICIC ACID COLUMNS
The data in Table 3 represent the recovery of total phosphorus from the preinhibitor fractions (C:M, 4:1) of duplicate silicic acid columns. Plasma and red cell lipids were those shown in Table 1 . In all but columns 7 and 8, the original lipid sample was divided equally between the duplicate columns. In columns 7 and 8, where the lipid applied was approximately twice as much as in the preceding six columns, the phosphorus recovered in the preinhibitor fraction was not doubled. To ascertain whether this discrepancy was due to overloading the columns, the eluates which preceded (C:M, 9:1 plus C:M, 6:1) and followed (C:M, 1:9) the preinhibitor fraction (C:M, 4:1) were evaporated to near dryness. The residues were quantitatively transferred to thin-layer chromatography Ninhydrin positive preinhibitor spots on a thin-layer chromatography plate. The second spot appearing in dog RBC and human plasma samples is phosphatidyl serine.
plates and chromatographed. No preinhibitor was detected in either of these eluates, indicating that the compound was contained entirely within the expected fraction. Therefore, the discrepancy in phosphorus yield from the preinhibitor fraction in columns 7 and 8 was not due to loss of preinhibitor but to loss of some other phospholipid, possibly phosphatidyl serine. All eluates from the other 16 columns in this experiment were checked in exactly the same manner, and in all cases no loss of preinhibitor was detectable in the eluates collected before the preinhibitor fraction. The eluates (C:M, 1:9) following this fraction were free of preinhibitor in columns 1 to 8 (plasma lipids), but negligible traces were detected in this fraction from some of the remaining columns (9-18, red cell lipids). It follows that for quantitative purposes the indicated loads of red cell lipids approach the limit of column capacity by our elution scheme. In a second recovery experiment, preinhibitor fractions obtained from three samples of red cell lipid were concentrated, and a known amount of lipid phosphorus was reap-plied to each of three new columns, which were then eluted with all the solvent systems in the usual manner. Of 21 /xg of phospholipid phosphorus applied per column, an average of 19.8 /Jig was recovered in the preinhibitor fraction from these three columns (94.3% recovery).
CHROMATOGRAPHIC IDENTITY OF BLOOD PHOSPHOLIPID AND KIDNEY PREINHIBITOR
The preinhibitor isolated previously from kidney has been distinguished from phosphatidyl ethanolamine and phosphatidyl serine (1, 2) . A sample of the preinhibitor from the dog kidney was compared with the preinhibitor from dog plasma by two-dimensional thin-layer chromatography carried out in the same jar at the same time. As shown below, the R P values for preinhibitor from the two sources are nearly identical in both dimensions.
Sources of preinhibitor (dog)
Rr lit dimension lolvent=Wuthier 1
Rr 2d dimension ulventaiWuthler 3
Kidney
"standard" Plasma dogs migrated with the same R F as the plasma and kidney material.
Preinhibitor isolated from human plasma was chromatographed on a plate alongside total preinhibitor from the plasma (2.0 ml) and red cells (0.25 g of hemoglobin) from 2 normal dogs (Fig. 2) . The appearances of preinhibitor spots from both dogs are quite similar, and their R F is the same as that of the human preinhibitor. In the dog, the preinhibitor fractions derived from red cells invariably contained considerable quantities of phosphatidyl serine; little or none was detected in comparable fractions from 2.0 ml of plasma. Some phosphatidyl serine is seen behind the human plasma preinhibitor. No quantitative comparisons between human and dog inhibitor or phosphatidyl serine are intended in Figure 2 .
BIOLOGICAL ACTIVITY OF PREINHIBITOR FROM PLASMA AND RED CELLS
The results of representative experiments on inhibition are shown in Table 4 . Unless otherwise indicated, lipids tested in the incubation medium containing renin and its substrate were derived from the preinhibitor fraction eluted from silicic acid columns with C:M (4:1). As previously stated, lipids in the final fraction were those eluted from the column with C:M (1:9) after the preinhibitor fraction had been removed. Kidney preinhibitor refers to the "standard" material isolated and purified as described previously (1, 2) . A small aliquot of each of the preinhibitor fractions to be tested was checked by thin-layer chromatography to confirm the presence of preinhibitor. The final fractions (tubes 3 and 4) were checked in the same way. No preinhibitor was detected in these small aliquots from the final fractions, which contained considerable phospholipid, including phosphatidyl serine, but produced no significant renin inhibition. Some additional spots from these final fractions were visualized on chromatography sheets with iodine Values are mean ± SEM. Probability values are based on comparisons between individual data in each group and not on difFerences between paired data giving the value for each animal before and after nephrectomy. *P = < 0.001; t P = < 0.01; other differences are not significant.
vapor but not in the preinhibitor fractions from plasma or red cells (C:M, 4:1). It seems that, where present, phosphatidyl serine was probably the main significant contaminant of the preinhibitor. The results in Table 4 show that pure phosphatidyl serine was not inhibitory. It is unlikely, therefore, that where this phospholipid contaminated preinhibitor, it was contributing to the inhibition. In tube 5, almost 50% inhibition of angiotensin production was achieved with 1,5 mg of plasma preinhibitor in a system which generated 40
OrcmUuon Rtsttrcb, Vol. XXI, Oaobtr 1967 ng of angiotensin/ml during the 4-hr incubation period. This degree of inhibition is in reasonable agreement with the inhibition due to about 1 mg of standard preinhibitor from dog kidney (tube 10).
MEASUREMENTS IN BILATERALLY NEPHRECTOMIZED DOCS
Averages from duplicate determinations of lipid from plasma and red cells are presented in Table 5 . Hematocrits and plasma protein concentrations in nephrectomized animals were both about 12% lower than the corresponding normal values, The results presented in Table 6 indicate that total phosphorus concentration in blood and plasma had not increased'^ignificantly at this stage after bilateral nephrectomy. Lipid phosphorus was significantly higher only in red cells-which is possibly related to the rise in lipid concentration after nephrectomy (Table  5 ). At a blood hemoglobin concentration of 12.5 g/100 ml, 0.5 g of hemoglobin would be found in 4.0 ml of blood. Of this volume, approximately 2.2 ml would be plasma when the hematocrit is 45. From the results shown in Table 6 , it can be calculated (Table 4 ). However, in terms of the total lipid phosphorus, preinhibitor accounts for less than 1% of that in plasma and about 9% of that in erythrocytes.
The concentration of preinhibitor in dog plasma remained constant 48 hr after bilateral nephrectomy, while the level in red cells was, if anything, somewhat higher. However, the ratio of preinhibitor P in red cells to the total lipid P in red cells remained unchanged (Table  6 ).
Discussion
The presence of preinhibitor phospholipid in dog plasma and erythrocytes adds significance to its discovery in the kidney (1, 2) . Such evidence suggests the possibility that preinhibitor has both renal and extrarenal functions. Experiments with the preinhibitor in vitro (Table 4 ) indicate its ability to reduce significantly the amount of pressor material produced when renin is incubated with its crude substrate. Previous results suggest that the renin and substrate preparations used in the incubation system were contaminated with the lipase(s) responsible for converting preinhibitor to the active lysophospholipid (2) .
The quantity of preinhibitor which had to be added to achieve significant inhibition in vitro, though relatively high, is in line with the amount present in blood Normal dog blood appears to contain about 116 fig of preinhibitor phospholipid/ml, the majority of which is present in the erythrocytes. Factors controlling total blood concentration, and distribution between cells and plasma are unknown.
Daily intramuscular injections of 2.6 to 6.7 mg/kg of renin inhibitor caused significant lowering of blood pressure in rats with renal hypertension (1, 2) . No hemolysis or other ill effects have so far been detected in any recipient animals. The inhibitory effect of preinhibitor on renin was not produced by phosphatidyl ethanolamine, phosphatidyl serine, or prostaglandin E x and Ei-217 (2) .
The effect of preinhibitor on the reninsubstrate reaction prompted us to determine its concentration in blood before and after bilateral nephrectomy. It is well known that several mammalian species, including the dog, have pressor responses to infused renin that are far greater after bilateral nephrectomy than before (9")"; A number of authors have presented evidence suggesting that disappearance of a renal antihypertensive principle from the blood might be responsible for this phenomenon (10) (11) (12) . Our expectation that preinhibitor concentrations in blood might fall appreciably, 48 hr after bilateral nephrectomy, was not supported by the data ( Table 6 ). Interpretation of these results is difficult until it is known whether extrarenal tissues also produce preinhibitor and what factors regulate its concentration in blood. It may be that it is less important to measure blood levels of preinhibitor than to measure levels of the active lysophospholipid, or the enzyme(s) responsible for its production and destruction. Further studies are required to reveal the significance of preinhibitor and its physiological role relative to the reninangiotensin system.
